Plaintiffs Point To "Tellabs" In Pfizer Securities Suit

Law360, New York (July 12, 2007, 12:00 AM EDT) -- The lead plaintiffs in a securities fraud lawsuit against Pfizer Inc. over the drug giant's decision to scrap its highly anticipated cholesterol drug torcetrapib moved to bolster their case Wednesday, arguing that a recent U.S. Supreme Court decision lends weight to their scienter allegations.

Attorneys with Schoengold Sporn Laitman & Lometti, P.C., the firm representing the plaintiffs in the case, said in court documents filed in the U.S. District Court for the Southern District of New York that the High Court's June 21 decision in Tellabs...
To view the full article, register now.